In situ vaccination using unique tlr9 ligand k3-spg induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy

HIGHLIGHTS

• who: Hirokazu Okada from the DepartmentKyoto University have published the paper: In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy, in the Journal: Scientific Reports Scientific Reports of 20/09/2021
• what: To exclude dead cells from the analysis, a fixable viability stain 510 (BD Biosciences) was used.
• how: The authors investigated the antitumor effect of K3-SPG-ISV using a syngeneic pancreatic cancer model. In this study focusing on the clinical feasibility and advantages of ISV as mentioned in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.